Novellia

Summary

Novellia develops patient-permissioned health data infrastructure. Its public consumer product helps people centralize medical records from multiple providers, track symptoms, manage medications, and keep a more complete personal health history. Its life-sciences platform uses patient-authorized longitudinal data to support real-world evidence, HEOR, market access, clinical operations, medical affairs, and research workflows.

Novellia is best understood as a consent-centered health data infrastructure company, not as a diagnostic AI system or provider-facing clinical workflow tool. Its AI relevance sits in organizing, cleaning, linking, and enriching fragmented medical data so patients can better understand their own records and research teams can work from more complete longitudinal patient stories.

Why It Matters

Novellia matters because health AI depends on data quality, provenance, completeness, and consent. Many real-world datasets are fragmented across portals, providers, EHRs, labs, and care sites. Novellia’s public thesis is that patients themselves can become the organizing center for longitudinal health data when they are given tools to gather records and authorize research use.

As a Health AI category signal, Novellia shows the importance of infrastructure that sits upstream from models: permissioning, record retrieval, data cleaning, longitudinal structure, and research-grade data generation. That layer may become increasingly important as AI systems require better evidence, better context, and clearer consent boundaries.

Best Read As

Novellia is best read as a patient-permissioned real-world data and health records infrastructure company, not as a clinical decision support system, diagnostic AI company, or generic personal health app.

Its public positioning is closer to a consented longitudinal health-data platform than to a model provider. The consumer app is important, but the broader category role is the bridge between patient-controlled records and life-sciences evidence generation.

Domains

• Patient-permissioned health data
• Personal health records and medical-record aggregation
• Longitudinal real-world data
• Real-world evidence and HEOR support
• Life-sciences research infrastructure
• Patient-authorized registries
• Medical affairs, market access, clinical operations, and research workflows

Modalities

• Patient-authorized medical records
• Structured and unstructured clinical data
• Lab results, medications, visits, diagnoses, and provider records
• Symptom tracking, ePROs, and patient-reported journey data
• AI-enabled data cleaning, linking, deduplication, and enrichment
• Longitudinal patient story construction
• Anonymized and harmonized datasets for research use

Signal Indicators

• Novellia’s consumer site describes the product as a free personal health record tool for centralizing medical records.
• The App Store listing describes record aggregation, symptom tracking, and health data management across multiple doctors.
• Novellia’s life-sciences site states that every data point comes directly from the person it belongs to and is fully consented.
• The company describes its dataset as sourced directly from patients who use Novellia to unify health records across providers, EMRs, and care sites.
• Novellia states that its proprietary models clean, link, and enrich structured and unstructured medical data.
• Public materials describe use cases across HEOR, market access, clinical operations, medical affairs, commercial strategy, and R&D.
• Novellia has described patient-authorized longitudinal registries as an alternative to institution-bound EHR data sources.
• Public announcements describe Project EVEREST as an AI-enabled, patient-permissioned longitudinal registry focused on breast cancer care.

Architecture and Stance

Novellia’s architecture is publicly framed around patient-authorized data capture, longitudinal record assembly, AI-enabled data structuring, and research-ready evidence generation. The company’s model is not to buy brokered datasets or rely only on institution feeds. Its public stance is that every data point should come directly from the person it belongs to, with consent.

This makes Novellia structurally different from a general personal health app. The patient app is the entry point, but the infrastructure value sits in permissioned data provenance, record completeness, and longitudinal structure for life-sciences use cases.

Governance Posture

Novellia operates in a high-sensitivity data category. The strongest visible governance signals are patient permissioning, direct patient data sourcing, health-record centralization, privacy/data-consent disclosures, and explicit emphasis on anonymized or de-identified research contribution.

The main governance issue is not clinical autonomy, but data rights and research use. Novellia’s credibility depends on durable consent controls, transparency around data sharing, clear patient understanding, strong privacy practices, and careful separation between record organization, research evidence generation, and medical advice.

Scale and Trajectory

Novellia appears to be moving from personal health-record aggregation into a broader patient-powered real-world data infrastructure role. Public materials describe use by life-sciences teams across medical affairs, HEOR, market access, clinical operations, commercial strategy, and R&D.

The strongest trajectory is consented longitudinal data. If Novellia can maintain patient trust while producing research-grade datasets, it may become an important infrastructure layer for evidence generation, post-launch monitoring, care-gap analysis, and patient-centered registries.

Recent Public Updates

• Novellia Launches Project EVEREST described an AI-enabled, patient-permissioned longitudinal registry focused on real-world treatment adherence in breast cancer care.
• Novellia Life Sciences Platform describes patient-consented longitudinal data workflows for HEOR, market access, clinical operations, medical affairs, commercial strategy, and R&D teams.

What Is Still Unclear

Public information does not yet fully show how Novellia’s consent flows are experienced by patients over time, how often patients update or revoke research permissions, how dataset quality is independently audited, how de-identification risk is managed across rare or complex disease cohorts, or how biopharma users validate outputs across different research contexts.

The strongest current signal is patient-permissioned longitudinal data infrastructure, rather than proof that every dataset or registry use case has equivalent maturity, scale, or external validation.